Plasma cell leukemia

被引：24

作者：

Hayman S.R. ^{[1
]}

Fonseca R. ^{[1
]}

机构：

[1] Department of Hematology, Mayo Clinic, 200 First Street, SW, Rochester, 55905, MN

来源：

Current Treatment Options in Oncology | 2001年 / 2卷 / 3期

关键词：

Main Drug Interaction; Main Side Effect; Multiple Myeloma; Pamidronate; Total Body Irradiation;

D O I：

10.1007/s11864-001-0034-4

中图分类号：

学科分类号：

摘要：

Plasma cell leukemia (PCL) is a rare aggressive variant of multiple myeloma (MM) characterized by a fulminant course and poor prognosis. The median survival is measured in months. Therapy and prognosis partially depend on whether the disease presents de novo or as a secondary process involving the leukemic transformation of a previously diagnosed MM. Secondary PCL represents a terminal event for refractory/relapsed MM and is usually not responsive to any treatment modality. The optimal regimens for the treatment of primary PCL have not been firmly established. Induction with combination chemotherapy, followed by high-dose chemotherapy (preferably within the setting of a clinical trial), is the current recommended approach for eligible patients. © 2001, Current Science Inc.

引用

页码：205 / 216

页数：11

共 34 条

[1]

Dimopoulos M.A., Palumbo A., Delasalle K.B., Alexanian R., Primary plasma cell leukaemia, Br J Haematol, 88, pp. 754-759, (1994)

[2]

Blade J., Kyle R.A., Nonsecretory myeloma, immunoglobulin D myeloma, and plasma cell leukemia, Hematol Oncol Clin North Am, 13, pp. 1259-1272, (1999)

[3]

Noel P., Kyle R.A., Plasma cell leukemia: an evaluation of response to therapy, Am J Med, 83, pp. 1062-1068, (1987)

[4]

Garcia-Sanz R., Orfao A., Gonzalez M., Et al., Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics, Blood, 93, pp. 1032-1037, (1999)

[5]

Durie B.G., Salmon S.E., A clinical staging system for multiple myeloma, Cancer, 36, pp. 842-854, (1975)

[6]

Hogan W., Fonseca R., Rajkumar S., Et al., Plasma cell leukemia: long term follow up information, Proc ASCO, 18, (1999)

[7]

Perez-Simon J.A., Garcia-Sanz R., Tabernero M.D., Et al., Prognostic value of numerical chromosome aberrations in multiple myeloma: a FISH analysis of 15 different chromosomes, Blood, 91, pp. 3366-3371, (1998)

[8]

Pellat-Deceunynck C., Barille S., Jego G., Et al., The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma, Leukemia, 12, pp. 1977-1982, (1998)

[9]

Avet-Louiseau H., Daviet A., Brigardeau C., Et al., Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myelome and the Groupe Francais de Cytogenetique Hematologique, Blood, 97, pp. 822-825, (2001)

[10]

Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists’ Collaborative Group, J Clin Oncol, 16, pp. 3832-3842, (1998)

← 1 2 3 4 →